Prescott Group Reiterates Its Position Against Merger Between...
PIP ) has been terminated. In this way, PharmAthene has cancelled the special meeting of shareholders where they were supposed to vote on the merger between two companies.
PharmAthene terminates merger with Seattle biotech
Annapolis-based PharmAthene Inc. , a clinical-stage bio-defense company, announced Monday it has scrapped a planned merger with Seattle's Theraclone Sciences Inc. PharmAthene's pipeline includes a next-gen Anthrax vaccine candidate that would rival Emergent BioSolutions' Biothrax.
Theraclone Announces That the Merger Agreement With PharmAthene Has Been Terminated
Theraclone Sciences, Inc. announced today that it consented to PharmAthene's termination of the parties' definitive merger agreement.
Fri Nov 29, 2013
Prescott Group Urges PharmAthene Shareholders to Vote Against Proposed Theraclone Merger
Prescott Group Capital Management, a greater than 10% shareholder of PharmAthene, Inc. , who has previously urged shareholders to vote against the Theraclone merger based largely on the lack of proper disclosures, now questions the quality of due diligence performed by PharmAthene's Board of Directors after Theraclone announced on November 27, 2013 ... (more)
Wed Nov 27, 2013
Theraclone Provides Update on BARDA Funding Proposal for TCN-032 for Serious and Pandemic Flu
Theraclone submitted the proposal on August 29, 2013, to apply for government funding to advance development of TCN-032 into Phase 2 clinical development for serious influenza disease, including pandemic flu.
Tue Nov 26, 2013
Prescott Group Capital Management Provides Update on Its Discussions with PharmAthene
Phil Frohlich 's Prescott Group Capital Management, has provided, in a newly amended filing with the Securities and Exchange Commission, an update on its negotiations with the board of PharmAthene, Inc. (NYSEMKT According to the filing, the board declined both proposals for a meeting, stating that the fund should have submitted a statement with the ... (more)
Wed Nov 13, 2013
Phil Frohlich's Prescott Group Requests Special Meeting at PharmAthene
Phil Frohlich 's Prescott Group Capital Management has requested a special meeting for the shareholders of PharmAthene, Inc. .
Mon Nov 11, 2013
New PharmAthene SparVaxA Anthrax Vaccine Data Published In Clinical and Vaccine Immunology
PharmAthene, Inc. , a biodefense company developing medical countermeasures against biological and chemical threats, today announced that new data from the Company's next-generation SparVax recombinant protective antigen anthrax vaccine program were published in the November issue of the American Society for Microbiology peer-reviewed journal ... (more)
Thu Nov 07, 2013
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
On track to commence SparVax Phase 2 clinical trial -- Presented new SparVax anthrax vaccine data at the 2013 Bacillus-ACT International Conference and the 53 Annual Interscience Conference on Antimicrobial Agents and Chemotherapy -- Advanced proposed merger with Theraclone Sciences; filed amended Form S-4 registration statement and set date for ... (more)
Mon Nov 04, 2013
Theraclone Sciences' Monoclonal Antibody Candidate PGT121...
Theraclone Sciences, Inc., a therapeutic antibody discovery and development company, today announced that collaborators published data in the October 30th issue of Nature regarding an antibody discovered by Theraclone and the International AIDS Vaccine Initiative with significant potency and breadth against human immunodeficiency virus .